RORγt-Expressing Tregs Drive the Growth of Colitis-Associated Colorectal Cancer by Controlling IL6 in Dendritic Cells

Tumor-infiltrating RORγt+FoxP3+ Tregs were found to be a stable population in cancer-associated colitis. In a murine model, this population accumulates in chronically inflamed colons and sustains dysplastic cell STAT3 activation and proliferation, while preventing FoxO3-mediated suppression of IL6. Chronic inflammation drives colitis-associated colorectal cancer (CAC) in inflammatory bowel disease (IBD). FoxP3+ regulatory T cells (Treg) coexpressing the Th17-related transcription factor RORγt accumulate in the lamina propria of IBD patients, where they are thought to represent an intermediate stage of development toward a Th17 proinflammatory phenotype. However, the role of these cells in CAC is unknown. RORγt+FoxP3+ cells were investigated in human samples of CAC, and their phenotypic stability and function were investigated in an azoxymethane/dextran sulfate sodium model of CAC using Treg fate-mapping reporter and Treg-specific RORγt conditional knockout mice. Tumor development and the intratumoral inflammatory milieu were characterized in these mice. The functional role of CTLA-4 expressed by Tregs and FoxO3 in dendritic cells (DC) was studied in vitro and in vivo by siRNA-silencing experiments. RORγt expression identified a phenotypically stable population of tumor-infiltrating Tregs in humans and mice. Conditional RORγt knockout mice showed reduced tumor incidence, and dysplastic cells exhibited low Ki67 expression and STAT3 activation. Tumor-infiltrating DCs produced less IL6, a cytokine that triggers STAT3-dependent proliferative signals in neoplastic cells. RORγt-deficient Tregs isolated from tumors overexpressed CTLA-4 and induced DCs to have elevated expression of the transcription factor FoxO3, thus reducing IL6 expression. Finally, in vivo silencing of FoxO3 obtained by siRNA microinjection in the tumors of RORγt-deficient mice restored IL6 expression and tumor growth. These data demonstrate that RORγt expressed by tumor-infiltrating Tregs sustains tumor growth by leaving IL6 expression in DCs unchecked. Cancer Immunol Res; 6(9); 1082–92. ©2018 AACR.

[1]  M. Beckstette,et al.  Foxp3+ T cells expressing RORγt represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation , 2015, Mucosal Immunology.

[2]  C. Gasche,et al.  IL10R2 Overexpression Promotes IL22/STAT3 Signaling in Colorectal Carcinogenesis , 2015, Cancer Immunology Research.

[3]  T. Macdonald,et al.  Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth , 2014, Oncogene.

[4]  Hiroshi Takayanagi,et al.  Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis , 2013, Nature Medicine.

[5]  J. Bluestone,et al.  Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. , 2013, Immunity.

[6]  G. Kaplan,et al.  Increased Prevalence of Circulating Novel IL-17 Secreting Foxp3 Expressing CD4+ T Cells and Defective Suppressive Function of Circulating Foxp3+ Regulatory Cells Support Plasticity Between Th17 and Regulatory T Cells in Inflammatory Bowel Disease Patients , 2013, Inflammatory bowel diseases.

[7]  D. Campbell,et al.  T-bet+ Treg Cells Undergo Abortive Th1 Cell Differentiation due to Impaired Expression of IL-12 Receptor β2 , 2012, Immunity.

[8]  G. Schiechl,et al.  Deletion of Foxp3+ regulatory T cells in genetically targeted mice supports development of intestinal inflammation , 2012, BMC Gastroenterology.

[9]  J. Chiang,et al.  Tumor-Derived Chemokine CCL5 Enhances TGF- b – Mediated Killing of CD8 þ T Cells in Colon Cancer by T-Regulatory Cells , 2012 .

[10]  Herman Waldmann,et al.  Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. , 2012, Immunity.

[11]  Keji Zhao,et al.  GATA3 controls Foxp3⁺ regulatory T cell fate during inflammation in mice. , 2011, The Journal of clinical investigation.

[12]  A. Rizzo,et al.  Involvement of interleukin-21 in the regulation of colitis-associated colon cancer , 2011, The Journal of experimental medicine.

[13]  Y. Wan,et al.  An essential role of the transcription factor GATA-3 for the function of regulatory T cells. , 2011, Immunity.

[14]  Ke Wu,et al.  IL-17+ Regulatory T Cells in the Microenvironments of Chronic Inflammation and Cancer , 2011, The Journal of Immunology.

[15]  J. Galon,et al.  Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. , 2011, Cancer research.

[16]  P. Tassone,et al.  Regulatory (FoxP3+) T-cell Tumor Infiltration Is a Favorable Prognostic Factor in Advanced Colon Cancer Patients Undergoing Chemo or Chemoimmunotherapy , 2010, Journal of immunotherapy.

[17]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[18]  M. Hoch,et al.  FOXO-dependent regulation of innate immune homeostasis , 2010, Nature.

[19]  A. Rudensky,et al.  CD4+ Regulatory T Cells Control TH17 Responses in a Stat3-Dependent Manner , 2009, Science.

[20]  D. Sargent,et al.  Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. , 2009, Gastroenterology.

[21]  J. Bluestone,et al.  Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo , 2009, Nature Immunology.

[22]  L. Bradley.  Faculty Opinions recommendation of The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. , 2009 .

[23]  J. Bluestone,et al.  Plasticity of CD4(+) FoxP3(+) T cells. , 2009, Current opinion in immunology.

[24]  D. Littman,et al.  Plasticity of CD4+ T cell lineage differentiation. , 2009, Immunity.

[25]  Daniel R. Beisner,et al.  Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells. , 2009, Nature immunology.

[26]  Kazuhiko Yamamoto,et al.  Faculty Opinions recommendation of Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. , 2009 .

[27]  G. Ingravallo,et al.  p38α blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1α- to FoxO-dependent transcription , 2009, Cell Death and Differentiation.

[28]  Daniel J. Campbell,et al.  T-bet controls regulatory T cell homeostasis and function during type-1 inflammation , 2009, Nature Immunology.

[29]  Ozge Canli,et al.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. , 2009, Cancer cell.

[30]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[31]  N. Zeps,et al.  Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[33]  Jon Clardy,et al.  FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells , 2008, Molecular Cancer Therapeutics.

[34]  Shimon Sakaguchi,et al.  Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation , 2008, Proceedings of the National Academy of Sciences.

[35]  D. Riethmacher,et al.  In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORγt+ T cells , 2008, The Journal of experimental medicine.

[36]  E. Lam,et al.  The emerging roles of forkhead box (Fox) proteins in cancer , 2007, Nature Reviews Cancer.

[37]  M. Neurath,et al.  High resolution colonoscopy in live mice , 2006, Nature Protocols.

[38]  T. Okanoue,et al.  Interferon‐gamma is causatively involved in experimental inflammatory bowel disease in mice , 2006, Clinical and experimental immunology.

[39]  D. Littman,et al.  The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells , 2006, Cell.

[40]  M. Neurath,et al.  IL-6 Signaling Promotes Tumor Growth in Colorectal Cancer , 2005, Cell cycle.

[41]  Ciriana Orabona,et al.  CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86 , 2004, Nature Immunology.

[42]  Stefan Wirtz,et al.  TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling , 2004 .

[43]  R. Kiesslich,et al.  TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. , 2004, Immunity.

[44]  Jonathan D. Hron,et al.  Regulation of NF-kappaB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a. , 2004, Immunity.

[45]  J. Fox,et al.  CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. , 2003, Cancer research.

[46]  Alastair Forbes,et al.  Severity of colonic inflammation is a risk factor for dysplasia in ulcerative colitis , 2003 .

[47]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[48]  K. Abrams,et al.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis , 2001, Gut.

[49]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[50]  D. Littman,et al.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. , 2006, Cell.